文献速递细胞病理与分子病理

甲状腺细胞学涂片:ThyroSeq检测的未开发资源

Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
PubMed 文献 · Cancer Cytopathol · 2020-07-22

本研究评估了甲状腺细针穿刺(FNA)细胞学涂片进行ThyroSeq检测的性能。31例涂片中81%适合分析,Pap染色涂片100%适合,DQ染色涂片65%适合。与新鲜FNA样本相比,突变和基因表达改变一致率100%,融合96%,拷贝数改变94%。结论认为细胞量充足的涂片可用于ThyroSeq基因组分类器检测。

要点

  • 细胞学涂片(尤其Pap染色)可用于ThyroSeq检测,适合率约80%。
  • 涂片与新鲜FNA样本的遗传学改变检测一致率高(94%–100%)。
  • 涂片需至少200–300个细胞(1–3张玻片)方适合分析。

核心结论

  • 细胞量充足的甲状腺FNA细胞学涂片可成功用于ThyroSeq基因组分类器检测,约80%病例可行,Pap染色涂片成功率更高。
  • 与保存液中的FNA样本相比,涂片可准确检测94%–100%的不同遗传学改变,验证了涂片作为替代方案的可行性。

研究设计与样本

  • 研究使用风干Diff-Quik(DQ)染色和酒精固定Papanicolaou(Pap)染色涂片,确定所需细胞量和突变检测灵敏度,并比较同一结节涂片与新鲜FNA样本的ThyroSeq v3基因组分类器结果。

主要发现

  • 31例细胞学涂片中25例(81%)适合ThyroSeq分析,包括14例Pap染色涂片(100%)和11例DQ染色涂片(65%),6例DQ染色涂片(35%)RNA测序失败。
  • 检测分子改变的总体准确率为98%,突变和基因表达改变一致率100%,融合一致率96%,拷贝数改变一致率94%。
  • 涂片在1–3张玻片中存在至少200–300个细胞时适合ThyroSeq分析;ThyroSeq可检测等位基因频率低至5%的所有研究突变和低至1%的BRAF突变。
  • 涂片检测在所有原分类为阳性的结节中均获得阳性ThyroSeq GC结果。

关键数值与推荐

  • 涂片适合ThyroSeq分析的细胞量要求:1–3张玻片中存在至少200–300个细胞。
  • 突变检测灵敏度:所有研究突变低至5%等位基因频率,BRAF突变低至1%等位基因频率。
  • 涂片与新鲜FNA样本的一致率:突变和基因表达改变100%,融合96%,拷贝数改变94%。

临床怎么用

  • 对于细胞学性质未定的甲状腺结节,当新鲜FNA样本不可及时,可使用细胞量充足的细胞学涂片(优先Pap染色)进行ThyroSeq检测。

局限性

  • DQ染色涂片有35%因RNA测序失败而不适合分析。
  • 研究样本量较小(31例涂片)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular testing of thyroid nodules with indeterminate fine-needle aspiration (FNA) cytology is commonly used to guide patient management and is typically performed on freshly collected FNA samples. In this study, the authors evaluated the performance of the ThyroSeq test in cytology smear slides. METHODS: Air-dried Diff-Quik (DQ)-stained and alcohol-fixed Papanicolaou (Pap)-stained smears were used to determine required cellularity and sensitivity of mutation detection and to compare ThyroSeq v3 Genomic Classifier (GC) results obtained in cytology smears and fresh FNA samples from the same nodules. RESULTS: ThyroSeq testing of 31 cytology smears revealed that 25 smears (81%) were adequate for ThyroSeq analysis, including 14 Pap-stained smears (100%) and 11 DQ-stained smears (65%), whereas 6 DQ-stained smears (35%) failed RNA sequencing. The overall accuracy for detecting molecular alterations was 98%, with 100% concordance for mutations and gene expression alterations, 96% concordance for fusions, and 94% concordance for copy number alterations. Cytology smears were adequate for ThyroSeq analysis when at least 200 to 300 cells were present in 1 to 3 slides. ThyroSeq detected all studied mutations down to 5% allele frequency and BRAF mutations down to 1% allele frequency. Testing of smears yielded a positive ThyroSeq GC result in all nodules originally classified as positive. CONCLUSIONS: Thyroid FNA cytology smear slides with adequate cellularity can be successfully used for ThyroSeq GC testing in approximately 80% of cases, with an even higher success rate in Pap-stained smears. Compared with FNA samples collected into preservative solution, 94% to 100% of different genetic alterations could be accurately detected in smears, validating cytology smears as an alternative for ThyroSeq testing in patients with indeterminate thyroid cytology.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Nikiforova MN, Lepe M, Tolino LA, et al. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathol. 2020. PMID: 32697051. doi:10.1002/cncy.22331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。